

The lack of biological data **kills**.

...now isn't that a bold statement.



Clinic

Antibiotics prescribed **blind** → resistance.
resistance. GRAM projects **8M+ deaths/yr by**
deaths/yr by 2050.



Field

Crops lost to **unseen pathogens** — or saved
saved only by mass pesticide spraying.



Supply chain

Blind to **folic acid, quinine** — fortified food,
food, malaria prevention, even your G&T.
G&T.

We track the world **blind**.

We can get it. Just **slowly, expensively, and never at scale.**

SLOW

Days, not minutes — culture, PCR and the lab queue sit between question and answer.

EXPENSIVE

Thermocyclers, cold chain, trained technicians — out of reach for most clinics and farms.

NOT SCALABLE

Only where a lab reaches — never in situ, never everywhere, never in real time.

THE PROMISE

What if we could measure **any biomarker** — at scale, in situ, with **lab-grade accuracy** , for a **fraction of the price?**

THE TEAM IS THE PROOF

We're **Superposition.bio** — Imperial College bioengineers, founders and operators.



Dr. Hong Seok (Andrew) Lee

CO-FOUNDER & CTO

Imperial PhD · Güder Lab ·
ELLA co-inventor



Jaime Aguilera Garcia

CO-FOUNDER & CEO

Biomedical engineer · multiple-time
founder & operator



Prof. Firat Güder

**ACADEMIC CO-FOUNDER &
CSO**

World-leading expert in intelligent
interfaces & sensors

Behind the platform — inventors **Dr. José Flauzino**, **Laura Gonzalez Macia** & the wider Güder Research Group.


Imperial College spinout

\$2M+ equity-free

Cloud
Database

Mapping


Share



Power

Data

ELLA Cassette



PROOF · IT MATCHES THE LAB, EVERY TIME

Not a promise — **measured.**

89%

agreement with **RT-qPCR** — cassava disease, in the field

>95%


agreement with **ELISA**, the lab immunoassay gold standard

R^2 0.98

vs **chemiluminescence** — clinical procalcitonin, 27 samples / 9 patients

Three gold standards, across field and clinic. **That is the de-risking.**

Receiver Operator Characteristics Analysis for Cassava Disease



Each use case is a multi-billion-dollar market — and only **the way in.**

CLINICAL · AMR

~\$5B

AMR diagnostics — inside a **~\$110B** in-vitro-diagnostics market.

FOOD SAFETY


~\$26B

Food-safety testing today — → **~\$50B by 2034.**
2034.

PHARMA SUPPLY CHAIN

Multi-\$B

Quality & integrity testing inside a **\$1T+** pharma industry.



\$130B+ addressable today

...a sliver of the **trillions** spent on health · food · pharma

The industry is increasingly hungry for high-value data — and our hardware is the moat.

From Gates-funded impact → **paid pilots** → **the markets that pay.**

NOW · GATES-FUNDED

Proven in the field

Several years applying the tech in less-regulated, critical-need settings. **£1M+ equity-free.**

Gates Foundation



EMERGING · PILOTS

Clinical + paid pilots

Malnutrition & food security today;
scaled horizontally in the lab to **clinical**.
In active **OEM** discussions for paid
pilots; commercialising existing
projects.



NEXT · ASPIRATIONAL


Higher-value markets

Scale to lucrative use cases, competing
directly with **lab-grade diagnostics**.

THE ASK

We're raising
\$8M.

To de-risk the market opportunity — and begin capturing revenue, at scale.



SUPERPOSITION.BIO

Biomarker intelligence platform · point-of-care diagnostics for rapid detection of biological threats

Thank you for listening.